Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multisite study that aims to improve clinical trials for the prevention and treatment of Alzheimer’s disease (AD).[1] This cooperative study combines expertise and funding from the private and public sector to study subjects with AD, as well as those who may develop AD and controls with no signs of cognitive impairment.[2] Researchers at 63 sites in the US and Canada track the progression of AD in the human brain with neuroimaging, biochemical, and genetic biological markers.[2][3] This knowledge helps to find better clinical trials for the prevention and treatment of AD. ADNI has made a global impact,[4] firstly by developing a set of standardized protocols to allow the comparison of results from multiple centers,[4] and secondly by its data-sharing policy which makes available all at the data without embargo to qualified researchers worldwide.[5] To date, over 1000 scientific publications have used ADNI data.[6] A number of other initiatives related to AD and other diseases have been designed and implemented using ADNI as a model.[4] ADNI has been running since 2004 and is currently funded until 2021.[7]
Source: Wikipedia, https://en.wikipedia.org/wiki/Alzheimer%27s_Disease_Neuroimaging_Initiative
Paper | Code | Results | Date | Stars |
---|